FORA Capital’s Sage Therapeutics SAGE Stock Holding History

FORA Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,491	Closed	-$83.4K	–	667
2025 Q1	$83.4K	Buy	+10,491	New	+$76.8K	0.01%	467
2021 Q1	–	Sell	-3,572	Closed	-$309K	–	1051
2020 Q4	$309K	Buy	+3,572	New	+$263K	0.05%	409
2020 Q3	–	Sell	-5,268	Closed	-$219K	–	940
2020 Q2	$219K	Sell	5,268 -5,047	-49%	-$183K	0.08%	312
2020 Q1	$296K	Buy	+10,315	New	+$597K	0.06%	349

Other funds holding SAGE

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

FORA Capital's SAGE Position: Q2 2025 in Review

FORA Capital sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 10,491 shares — an estimated $83.4K sold.

FORA Capital first reported a position in SAGE in Q1 2020 and held it in 4 quarters. The position peaked at $309K in Q4 2020. 192 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

FORA Capital reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
FORA Capital sold 10,491 Sage Therapeutics shares in Q2 2025, an estimated $83.4K.
FORA Capital first reported a position in Sage Therapeutics in Q1 2020 and held it in 4 quarters.
FORA Capital's Sage Therapeutics position peaked at $309K in Q4 2020.
192 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on FORA Capital's 13F filing for Q2 2025, filed 13 Aug 2025.